Silo Pharma Reports Third Quarter 2026 Financial Results
Silo Pharma reported its financial results for the third quarter of 2026, showing zero revenue and a continued operating loss.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Silo Pharma reported its financial results for the third quarter of 2026, showing zero revenue and a continued operating loss.
Silo Pharma, Inc. completed a private placement of common shares and pre-funded warrants, raising approximately $815,000 in gross proceeds.
Filed: 2026-11-06 AccNo: 0001213900-26-116982 Size: 738 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
-SEC Filing
On October 1, 2026, Silo Pharma, Inc. (the "Company") entered into an asset purchase agreement (the "Agreement") with Norsight Consulting Inc., an Arkansas corporation (the "Seller"). Pursuant to